TickerKhojComparison · NSE · data 2026-11-03
Biocon Limited vs Glenmark Pharmaceuticals Limited
In plain words
Size: Glenmark Pharmaceuticals Limited is about 1.1 times the market value of Biocon Limited.
Valuation (P/E): Biocon Limited 105.5 vs Glenmark Pharmaceuticals Limited 37.4.
Return on equity: Glenmark Pharmaceuticals Limited 14.1% vs Biocon Limited 1.4%.
Profit growth over 3 years: Glenmark Pharmaceuticals Limited 66.1% a year vs Biocon Limited -5.9% a year.
Debt to equity: Biocon Limited 0.45 vs Glenmark Pharmaceuticals Limited 0.06.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BIOCON | GLENMARK | |
|---|---|---|
| Price | ₹354.7 | ₹2,382 |
| Market cap | ₹57,310 cr | ₹65,137 cr |
| P/E | 105.5 | 37.4 |
| P/B | 1.6 | — |
| ROE | 1.4% | 14.1% |
| ROCE | 3.5% | 29.2% |
| Debt / equity | 0.45 | 0.06 |
| Operating margin | 8.6% | 20.2% |
| Dividend yield | 0.14% | 0.22% |
| Sales growth, 3 years (yearly) | 15.2% | 13.6% |
| Profit growth, 3 years (yearly) | -5.9% | 66.1% |
| 1-year return | -6.2% | 26.5% |
| Revenue, last 12 months | ₹17,321 cr | ₹17,737 cr |
| Net profit, last 12 months | ₹495 cr | ₹1,798 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹141 cr | ₹483 cr |
| Quarter profit vs a year earlier | +349.4% | +930.3% |
| Promoter holding | 44.68% | 46.65% |
| Health check | Weak (3.6/10) | Strong (8.3/10) |
Common questions
Which has a higher P/E, Biocon Limited or Glenmark Pharmaceuticals Limited?
Biocon Limited trades at the higher P/E (105.5 against 37.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Glenmark Pharmaceuticals Limited (14.1% against 1.4%).
Which carries more debt?
Biocon Limited has the higher debt-to-equity ratio (0.45 against 0.06).